Skip to main content
Clinical Trials/NL-OMON50556
NL-OMON50556
Completed
Not Applicable

Fluorescence Molecular Endoscopy and Molecular Fluorescence-guided Surgery of locally advanced rectal cancer using cetuximab-IRDye800CW: a single-center feasibility safety study. - TRACT-II: Fluorescence Endoscopy and Surgery of Rectal Cancer

niversitair Medisch Centrum Groningen0 sites13 target enrollmentTBD

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Rectal cancer
Sponsor
niversitair Medisch Centrum Groningen
Enrollment
13
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
December 31, 2022
Last Updated
2 years ago
Study Type
Interventional

Investigators

Eligibility Criteria

Inclusion Criteria

  • \- Locally advanced rectal cancer, in multi\-disciplinary colorectal oncology
  • meeting agreed on long course neoadjuvant chemoradiotherapy, followed by
  • surgical removal of the primary tumor;
  • \- Age \>\= 18 years;
  • \- Written informed consent.

Exclusion Criteria

  • \- Medical or psychiatric conditions that compromise the patient\*s ability to
  • give informed consent;
  • \- Concurrent uncontrolled medical conditions;
  • \- Pregnancy or breast feeding. A negative pregnancy test must be available for
  • women of childbearing potential (i.e. premenopausal women with intact
  • reproductive organs and women less than two years after menopause);
  • \- Received an investigational drug within 30 days prior to the dose of
  • cetuximab\-IRDye800CW;
  • \- History of infusion reactions to cetuximab or other monoclonal antibodies;
  • \- Had within 6 months prior to enrollment: myocardial infarction,

Outcomes

Primary Outcomes

Not specified

Similar Trials